Peer Review History
| Original SubmissionJuly 12, 2021 |
|---|
|
PONE-D-21-22682Annual HIV screening rates for HIV-negative men who have sex with men in primary carePLOS ONE Dear Dr. Harper, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The manuscript has been evaluated by two reviewers, and their comments are available below. The reviewers have raised a number of concerns that need attention. They request additional information on methodological aspects of the study, revisions to the statistical analyses and inclusion/exclusion criteria for patients. Could you please revise the manuscript to carefully address the concerns raised? Please submit your revised manuscript by Jan 22 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Elisa Panada Associate Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Increasing rates of routine HIV screening in primary care practices is critical to ending the HIV epidemic. As such, the manuscript addresses an important issue. However, there are several points that I feel require clarification. (1) Please provide a justification for limiting the sample to ages 18 to 45. The CDC recommendations are not limited to men in these age groups, so I see no reason not to include men of all ages. In fact, I would expect disparities in rates of testing by age to be even greater if older men had been included in the sample. (2) Please also provide some discussion about how reliably data on sexual orientation are actually reported in the EHR. The authors do not mention any missing data on this variable, but I can't believe that there were no cases with sexual orientation excluded. Depending on the size of the sample, it may be necessary to run the analyses with three groups (MSM, non-MSM, and missing). (3) Please reference the tables/figures in the narrative portion of the text to help guide the reader. (4) I do not understand why the authors chose to examine the data across years. Is there any reason to expect an increase in HIV screening over the three-year period? I see no justification for that and it does not make sense to me. The question is about an individual's receipt of an HIV screening test, so I would have expected the analysis to focus at the individual level to see if any screening had occurred, controlling for the number of days/years the individual was included in the sample. Those with data across all three calendar years would have more opportunity to have a screening test than those who were in the sample for only one year. The finding of significant differences by year but no significance by the CMH test was confusing at first, because the authors provided no justification for expecting changes in screening patterns by year. The approach to analysis that I have suggested seems to me more in line with the stated objectives of the study. (5) On a related note, in line 190, the authors note that the lack of an increasing in screening is "a disquieting finding." The low level of testing overall is certainly disquieting, but since the authors have not indicated a reason to expect an increase in annual rates of screening, this finding in and of itself is not especially "disquieting." (6) Lines 165-166 appear to be missing something - the sentence is incomplete. (7) The Limitations section should be expanded to include more discussion of the reliability of the methods used. Do the authors have any means to determine how regularly clinicians include in their notes discussions with patients about matters such as HIV testing, especially if the patient refused to be tested? (8) Please provide details within the text regarding which characteristics the study's sample "matches the distribution in the state of Michigan." Is that only in regards to the percentage of men identified as MSM (4.1%) or is that across other demographic characteristics? If it is only in terms of the percentage, then the authors' claims of generalizability cannot be substantiated. It could be that the percentage is similar but that the study sample includes a higher percentage of white MSM than found in the state as a whole. Reviewer #2: Thank you for allowing me to review your manuscript. Your research is clearly communicated and has meaningful implications to improve clinical practice. Please see a few comments/thoughts I had while reviewing. on page 6, line 81, you mention non-MSM and state bi-sexual men. I understand those who may not be aware of their sexual identity, but was curious why you did not include bi-sexual men as MSM? Are you suggesting here that the bi-sexual men may not have engaged in a sexual encounter with another man or are you just directly placing bisexual men in a "non MSM" category? Another question I had was the distribution of race/age based on practice setting. This is clearly not a focus of your work, but as you noted, STI clinics and ER's are frequently used sites; however, because you are the first to describe this data, did you see any associations with race/ethnicity and practice setting? Again, a question I had while reading that may have implications for clinical intervention implementation. And as a total side note, it would be interesting to see if the age/race/ethnicity/gender of the provider showed any significant outcomes. it took me a few seconds to understand table 1, which made me wonder if it would make for a more clear presentation to have the M and SD in the column header. That is the format I think most readers are accustomed to seeing. Finally, please consider changing your conclusions section to a Discussion, followed by your important conclusion statement. You have many important points to address and separating the discussion from your suggested conclusions may better frame the entirety of your discussion as well as making the clinical implications stand out to readers. Thank you again for allowing me to review this manuscript. I enjoyed reading it and can clearly see the importance of this study. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-21-22682R1Annual HIV screening rates for HIV-negative men who have sex with men in primary carePLOS ONE Dear Dr. Harper, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ACADEMIC EDITOR: Thank you for the responsive edits to some of the reviewer comments. However, I am requesting that you please address additional comments from Reviewer 1. With these clarifications, the paper will be reconsidered to see if it is acceptable for publication. I believe it will contribute to the important need for clinicians to do more regular HIV testing particularly for MSM and others at high ongoing risk for HIV acquisition (e.g., PWID) Please submit your revised manuscript by Apr 14 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Dawn K. Smith Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: No Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed some of the questions I raised in my initial review, but a re-reading raised additional questions and some responses to earlier questions by myself and the other reviewer have not been adequately addressed. (1) The authors have clarified the source of information regarding sexual orientation. However, there remains some confusion. Over what timeframe was the question regarding sexual partner asked? Over the past year? Lifetime? The way I have seen this question asked in a clinical setting is in regard to sexual preference (male, female, or both). Maybe that is what the authors intended to say (i.e., preference rather than "having a sexual partner" which implies that the question refers to whether or not the patient has a current sexual partner)? In any case, current sexual partner is not necessarily indicative of sexual orientation, and that should be mentioned in the Limitations section. In the Materials and Methods section, the authors state that the non-MSM group includes "those with neither male nor female partner." I'm assuming that the authors mean that the person indicated that they were not sexually active but the wording is awkward since it could be taken to mean that the patient reported sexual activity with a non-human partner. The discussion is also confusing because, in their response to reviewer comments and Discussion, the authors now state that "Patients with missing data for sexual partner were not included in our analysis." If the authors mean that a person is missing data on sexual activity, then it would be better to simply say that in the methods section. In any case, the authors should state the number of cases excluded due to missing data. (2) How was the search of the encounter notes performed? Given the large number of encounters included in the study, I'm assuming this process was automated. The authors should provide more details regarding the methods of the search. The description is also unclear because the authors specifically reference "rates of HIV discussion among MSM." Table 2 suggests that the search was performed for all patients included in the study (i.e., including for non-MSM), but the description suggests otherwise. If the same procedure was followed for both groups (which I'm sure it was), then that should be stated clearly. Similarly, when describing the calculation of the annual testing rates, the authors only mention the calculation for MSM. For the sake of completeness, please indicate that the same procedure was completed separately for non-MSM. (3) Table 1 as reformatted remains confusing as the table headers do not align with the columns and the p-value column appears to be missing. I disagree with the authors' statement to the second reviewer that "we must keep the labeling as it is." There are ways to improve the presentation of the data and that should be done. Tables and Figures should stand on their own, so all necessary clarifications should be made. (4) In the first paragraph of the Results section, please take out the statement, "... consistent with state-specific data for generalizability." Per my earlier comments and the authors' acknowledgement, this statement is confusing and not valid in any case. Please also remove the reference to generalizability from the discussion section (i.e., the paragraph that starts, "Methodologically, while a strength...") or at least limit it the context of the clinical sites. (5) In the Discussion section, the authors state, "Our results also indicate that multi-level interventions with the health system, primary care physicians, and men themselves could be necessary to increase the HIV test ordering rate." The study does not address the specific barriers to testing, so this statement (even if true) is not specifically substantiated by the study. The authors may justify this statement on the basis of other research, but not on the basis of the study as reported. (6) Please provide the tables describing the logistic regression models. The discussion is difficult to follow without data to reference. Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Annual HIV screening rates for HIV-negative men who have sex with men in primary care PONE-D-21-22682R2 Dear Dr. Harper, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Dawn K. Smith Academic Editor PLOS ONE Additional Editor Comments (optional): Thank you for clearly addressing the major comments from reviewers. The paper is much improved. Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-22682R2 Annual HIV screening rates for HIV-negative men who have sex with men in primary care Dear Dr. Harper: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Dawn K. Smith Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .